Somatostatin Analogs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1062826
  • May 2021
  • Pharmaceuticals
  • 131 Pages
The Somatostatin Analogs Market research report comprises of an overall in depth-analysis such as market drivers, opportunities, restraints, latest developments and trends, segmentation of the market, competitive analysis, global as well as regional analysis by showcasing how each of these factors can improve the further growth of the market on an overall perspective. The report also showcases the overall market value which includes the historic data (2018-2019) and forecast data (2020-2028) generated through the revenue (USD Mn)
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Chiasma Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Ipsen Pharma, Midatech Pharma PLC, Novartis AG, Peptron, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Inc
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Coverage
With the beginning of the COVID-19 pandemic in early 2020, all major economies around the world enforced severe lockdown restrictions to curb the spread of the virus. Apart from a few sectors such as healthcare and related essential services, most of the industries suffered tremendously due to inability to function in a normal fashion. Moreover, even some of the essential sectors suffered due to delays caused by supply chain disruptions and other travel complexities. However, with massive vaccination drives in most of the developed economies, some of the economies across the world experienced economic recovery from 2021. The Somatostatin Analogs market is expected to gain momentum in such economies and probably recover some of the losses inflicted in the year 2020. With continued efforts towards curbing the virus in the developing economies, the Somatostatin Analogs market is expected to attain Pre COVID-19 levels by mid-2022.

Somatostatin Analogs Report’s Assessment
The research report is formulated such that it offers a deep understating on the market drivers that are assimilating the growth of the market, the market opportunities that are going to provide future growth factors for the market and the market restraints which showcase the reasons as to why the market can get hampered and dissimilated. All these factors are considered keeping in view the historic and forecast analysis which can enlighten the above mentioned factors.

Thereby at a glance a reader can understand all the factors and prospects of the Somatostatin Analogs market and how it can assimilate and dissimilate based on each of the factors and figures mentioned in the report

Somatostatin Analogs Market Competitive and Premeditated Analysis
In the Somatostatin Analogs report major factors such latest tactical developments, competitors, research and development, participation of each region in the market and the competition among them, the latest news regarding company acquisitions and product launch, revenue of the competitors as well as the key offerings they provide all these factors are mentioned in the report with reasons to justify and understand them in depth.

The readers and purchaser of the Somatostatin Analogs research report can gain a comprehensive understanding of the market competition, the revenue of each major players and their contribution towards the market, attractive proposition analysis is provided in the report which sub divides the segments with respect to the largest segment that has contributed to the market growth and the fastest growing segment based on the size of the market as well as its overall appeal.
 
Major Key Players for Global Somatostatin Analogs Market:
The Somatostatin Analogs market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Chiasma Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Ipsen Pharma, Midatech Pharma PLC, Novartis AG, Peptron, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Inc

The Somatostatin Analogs market report showcases vast potentials of growth and assimilation which is going to provide the industry numerous opportunities to grow and generate revenue by understanding the segments and which segment is a potential part to increase the disposable income in the present and upcoming years.

Somatostatin Analogs Market Segmentation Analysis:
Each of the segment is explained in brief along with the revenue it generates for the market based on the historic and forecast data by highlighting the largest segment and the fastest growing segment with reasons to justify it.

The Global segmentation of the Somatostatin Analogs market:
by Indication
Acromegaly
NETs
Others
Type
Octreotide
Lanreotide
Pasireotide Diseases
Immunological Disorders
Respiratory Diseases
Cardiovascular Diseases
Neurological Disorders
Others
End User
Medical Device Companies
Biopharmaceutical Companies
Others

Regional Analysis of the Somatostatin Analogs market:
The Somatostatin Analogs market is dived based on different regions such as North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. And the analysis of each region is provided by highlighting the largest contribution region, the fastest growing region and the factors that is keeping the market active in the other regions is also mentioned in depth. Each regional segment also comprises of the revenue each segment holds in a specific region with reasons to justify the values.

By Regions:
  • North America (U.S and Canada)
  • Europe (U.K., Germany and France)
  • Asia Pacific (China, India and Japan)
  • Latin America (Mexico and Brazil)
  • Middle East and Africa (GCC Countries and South Africa)
 


Major Factors Included and highlighted in the Somatostatin Analogs report are as follows:
  • The overall market value along with historic and future data analysis.
  • The Growth drivers, opportunities and restraints are mention in detail.
  • The size of the entire Somatostatin Analogs market on a global perspective.
  • The CAGR value of the overall market from 2020 to 2028.
  • COVID-19 impact on the Somatostatin Analogs market and how it is coping up with the situation.
  • Major competitors and their contribution towards the market.
  • The segmentation analysis is included which provides a clear picture of the market bifurcation.
  • Tables and graphs that can easily been understood at a glance
  • Latest trends and news related to the Somatostatin Analogs market is included in the report.
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Somatostatin Analogs market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Somatostatin Analogs market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Somatostatin Analogs market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Somatostatin Analogs market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Somatostatin Analogs market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Chiasma Inc.
  • CRINETICS PHARMACEUTICALS
  • Dauntless Pharmaceuticals
  • Ipsen Pharma
  • Midatech Pharma PLC
  • Novartis AG
  • Peptron, Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceuticals Inc
  • Acromegaly
  • NETs
  • Others
  • Medical Device Companies
  • Biopharmaceutical Companies
  • Others

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Somatostatin Analogs Market Snapshot
          2.1.1. Global Somatostatin Analogs Market By Indication,2019
               2.1.1.1.Acromegaly
               2.1.1.2.NETs
               2.1.1.3.Others
          2.1.2. Global Somatostatin Analogs Market By End User,2019
               2.1.2.1.Medical Device Companies
               2.1.2.2.Biopharmaceutical Companies
               2.1.2.3.Others
          2.1.3. Global Somatostatin Analogs Market By End-use,2019
          2.1.4. Global Somatostatin Analogs Market By Geography,2019

3. Global Somatostatin Analogs Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Somatostatin Analogs Market Size (US$), By Indication, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Indication, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Indication, 2020
     4.2. Global Somatostatin Analogs Market Size (US$), By Indication, 2018 – 2028

5. Global Somatostatin Analogs Market Size (US$), By End User, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By End User, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By End User, 2020
     5.2. Global Somatostatin Analogs Market Size (US$), By End User, 2018 – 2028

6. Global Somatostatin Analogs Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Somatostatin Analogs Market Size (US$), By End-use, 2018 – 2028

7. Global Somatostatin Analogs Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Somatostatin Analogs Market Analysis, 2018 – 2028 
          7.2.1. North America Somatostatin Analogs Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Somatostatin Analogs Market Size (US$), By Indication, 2018 – 2028
          7.2.3. North America Somatostatin Analogs Market Size (US$), By End User, 2018 – 2028
          7.2.4. North America Somatostatin Analogs Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Somatostatin Analogs Market Analysis, 2018 – 2028 
          7.3.1.  Europe Somatostatin Analogs Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Somatostatin Analogs Market Size (US$), By Indication, 2018 – 2028
          7.3.3. Europe Somatostatin Analogs Market Size (US$), By End User, 2018 – 2028
          7.3.4. Europe Somatostatin Analogs Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Somatostatin Analogs Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Somatostatin Analogs Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Somatostatin Analogs Market Size (US$), By Indication, 2018 – 2028
          7.4.3. Asia Pacific Somatostatin Analogs Market Size (US$), By End User, 2018 – 2028
          7.4.4. Asia Pacific Somatostatin Analogs Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Somatostatin Analogs Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Somatostatin Analogs Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Somatostatin Analogs Market Size (US$), By Indication, 2018 – 2028
          7.5.3. Latin America Somatostatin Analogs Market Size (US$), By End User, 2018 – 2028
          7.5.4. Latin America Somatostatin Analogs Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Somatostatin Analogs Market Analysis, 2018 – 2028 
          7.6.1.  MEA Somatostatin Analogs Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Somatostatin Analogs Market Size (US$), By Indication, 2018 – 2028
          7.6.3. MEA Somatostatin Analogs Market Size (US$), By End User, 2018 – 2028
          7.6.4. MEA Somatostatin Analogs Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Somatostatin Analogs Providers
        8.4.1 Chiasma Inc.
                8.4.1.1 Business Description
                8.4.1.2 Chiasma Inc. Geographic Operations
                8.4.1.3 Chiasma Inc. Financial Information
                8.4.1.4 Chiasma Inc. Product Positions/Portfolio
                8.4.1.5 Chiasma Inc. Key Developments
        8.4.2 CRINETICS PHARMACEUTICALS
                8.4.2.1 Business Description
                8.4.2.2 CRINETICS PHARMACEUTICALS Geographic Operations
                8.4.2.3 CRINETICS PHARMACEUTICALS Financial Information
                8.4.2.4 CRINETICS PHARMACEUTICALS Product Positions/Portfolio
                8.4.2.5 CRINETICS PHARMACEUTICALS Key Developments
        8.4.3 Dauntless Pharmaceuticals
                8.4.3.1 Business Description
                8.4.3.2 Dauntless Pharmaceuticals Geographic Operations
                8.4.3.3 Dauntless Pharmaceuticals Financial Information
                8.4.3.4 Dauntless Pharmaceuticals Product Positions/Portfolio
                8.4.3.5 Dauntless Pharmaceuticals Key Developments
        8.4.4 Ipsen Pharma
                8.4.4.1 Business Description
                8.4.4.2 Ipsen Pharma Geographic Operations
                8.4.4.3 Ipsen Pharma Financial Information
                8.4.4.4 Ipsen Pharma Product Positions/Portfolio
                8.4.4.5 Ipsen Pharma Key Developments
        8.4.5 Midatech Pharma PLC
                8.4.5.1 Business Description
                8.4.5.2 Midatech Pharma PLC Geographic Operations
                8.4.5.3 Midatech Pharma PLC Financial Information
                8.4.5.4 Midatech Pharma PLC Product Positions/Portfolio
                8.4.5.5 Midatech Pharma PLC Key Developments
        8.4.6 Novartis AG
                8.4.6.1 Business Description
                8.4.6.2 Novartis AG Geographic Operations
                8.4.6.3 Novartis AG Financial Information
                8.4.6.4 Novartis AG Product Positions/Portfolio
                8.4.6.5 Novartis AG Key Developments
        8.4.7 Peptron, Inc.
                8.4.7.1 Business Description
                8.4.7.2 Peptron, Inc. Geographic Operations
                8.4.7.3 Peptron, Inc. Financial Information
                8.4.7.4 Peptron, Inc. Product Positions/Portfolio
                8.4.7.5 Peptron, Inc. Key Developments
        8.4.8 Pfizer Inc.
                8.4.8.1 Business Description
                8.4.8.2 Pfizer Inc. Geographic Operations
                8.4.8.3 Pfizer Inc. Financial Information
                8.4.8.4 Pfizer Inc. Product Positions/Portfolio
                8.4.8.5 Pfizer Inc. Key Developments
        8.4.9 Sun Pharmaceutical Industries Ltd
                8.4.9.1 Business Description
                8.4.9.2 Sun Pharmaceutical Industries Ltd Geographic Operations
                8.4.9.3 Sun Pharmaceutical Industries Ltd Financial Information
                8.4.9.4 Sun Pharmaceutical Industries Ltd Product Positions/Portfolio
                8.4.9.5 Sun Pharmaceutical Industries Ltd Key Developments
        8.4.10 Teva Pharmaceuticals Inc
                8.4.10.1 Business Description
                8.4.10.2 Teva Pharmaceuticals Inc Geographic Operations
                8.4.10.3 Teva Pharmaceuticals Inc Financial Information
                8.4.10.4 Teva Pharmaceuticals Inc Product Positions/Portfolio
                8.4.10.5 Teva Pharmaceuticals Inc Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Somatostatin Analogs Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Somatostatin Analogs Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Somatostatin Analogs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Somatostatin Analogs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Somatostatin Analogs Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Somatostatin Analogs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Somatostatin Analogs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Somatostatin Analogs Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Somatostatin Analogs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Somatostatin Analogs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Somatostatin Analogs Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Somatostatin Analogs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Somatostatin Analogs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Somatostatin Analogs Market Revenue, By Indication, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Somatostatin Analogs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Somatostatin Analogs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Somatostatin Analogs: Market Segmentation 
FIG. 2 Global Somatostatin Analogs Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Somatostatin Analogs Market, By Indication, 2019 (US$ Mn) 
FIG. 5 Global Somatostatin Analogs Market, By End User, 2019 (US$ Mn) 
FIG. 6 Global Somatostatin Analogs Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Somatostatin Analogs Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Somatostatin Analogs Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Somatostatin Analogs Providers, 2019
FIG. 11 Global Somatostatin Analogs Market Revenue Contribution, By Indication, 2019 & 2028 (Value %) 
FIG. 12 Global Somatostatin Analogs Market Revenue Contribution, By End User, 2019 & 2028 (Value %) 
FIG. 13 Global Somatostatin Analogs Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Somatostatin Analogs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Somatostatin Analogs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Somatostatin Analogs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Somatostatin Analogs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Somatostatin Analogs Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Somatostatin Analogs market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Somatostatin Analogs Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Somatostatin Analogs Market Value, By Segment1, 2018 – 2028
TABLE  North America Somatostatin Analogs Market Value, By Segment2, 2018 – 2028
TABLE  North America Somatostatin Analogs Market Value, By Country, 2018 – 2028
TABLE  Europe Somatostatin Analogs Market Value, By Segment1, 2018 – 2028
TABLE  Europe Somatostatin Analogs Market Value, By Segment2, 2018 – 2028
TABLE  Europe Somatostatin Analogs Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Somatostatin Analogs Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Somatostatin Analogs Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Somatostatin Analogs Market Value, By Country, 2018 – 2028
TABLE  Latin America Somatostatin Analogs Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Somatostatin Analogs Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Somatostatin Analogs Market Value, By Country, 2018 – 2028
TABLE  MEA Somatostatin Analogs Market Value, By Segment1, 2018 – 2028
TABLE  MEA Somatostatin Analogs Market Value, By Segment2, 2018 – 2028
TABLE  MEA Somatostatin Analogs Market Value, By Country, 2018 – 2028
TABLE  Chiasma Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  CRINETICS PHARMACEUTICALS: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Dauntless Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Ipsen Pharma: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Midatech Pharma PLC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Peptron, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sun Pharmaceutical Industries Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Teva Pharmaceuticals Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Somatostatin Analogs Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Somatostatin Analogs Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Somatostatin Analogs Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Somatostatin Analogs Market, By Geography, 2019 (US$ Mn)
FIG.  Global Somatostatin Analogs Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Somatostatin Analogs Providers, 2016
FIG.  Global Somatostatin Analogs Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global NETs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Somatostatin Analogs Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Biopharmaceutical Companies Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)